Organon (Organon) Cash And Cash Equivalents : $693 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Organon Cash And Cash Equivalents?

Organon's quarterly cash and cash equivalents increased from Jun. 2023 ($326.00 Mil) to Sep. 2023 ($414.00 Mil) and increased from Sep. 2023 ($414.00 Mil) to Dec. 2023 ($693.00 Mil).

Organon's annual cash and cash equivalents declined from Dec. 2021 ($737.00 Mil) to Dec. 2022 ($706.00 Mil) and declined from Dec. 2022 ($706.00 Mil) to Dec. 2023 ($693.00 Mil).

Organon Cash And Cash Equivalents Historical Data

The historical data trend for Organon's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Cash And Cash Equivalents Chart

Organon Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

319.00

12.00

737.00

706.00

693.00

Organon Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial													706.00	459.00	326.00	414.00	693.00

Organon Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Organon (NYSE:OGN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Organon Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Organon's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Organon (Organon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

OGN:Mexico 1OGN:Italy 0A9W:UK 7XP:Germany

Address

30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302

Website

https://www.organon.com

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.

Executives

Kirke Weaver	officer: Gen. Counsel & Corp. Secy.	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco	director	ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman	officer: General Counsel	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco	officer: Corporate Controller	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler	officer: Chief Commercial Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita	officer: Head of Global Business Svcs	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr.	officer: Head of Manufacturing	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione	officer: Chief Human Resources Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah	director	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter	officer: Hd of Ext. Affairs and ESG	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan	officer: Head of Research & Development	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139